State of the Industry survey results
The mean forecast among survey respondents is 16.8%, much higher than Dr. Barlow's prediction. Understandably, members might estimate a high percentage, she says, because of the immediate effect they feel in their wallets when filling a prescription.
"Pharmacy is the area where you pay right out of your pocket at the time of service," she says, but adds that the real focus should be on services and procedures.
The greatest increase in pharmaceutical spending will be from specialty drugs, but that could slow down as competition in that area increases. Rising pharmaceutical spending can mean less overall healthcare spending because effective drug utilization as a first-line treatment can reduce the need for costlier, more complicated treatments later.
"The more you spend on the pharmacy sector, the better off you are in terms of medical spending," she says.
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
Extending the Capabilities of the EHR Through Automation
August 2nd 2023Welcome back to another episode of "Tuning In to the C-Suite," where Briana Contreras, an editor of Managed Healthcare Executive, had the pleasure of chatting with Cindy Gaines, chief clinical transformation officer at Lumeon.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
In this second part of a video series, AMCP CEO Susan Cantrell addressed the impact of high prescription drug prices on underserved communities, highlighting disparities in access caused by the pandemic's effects on minority populations. On the industry blame debate, she urged collaborative solutions, mentioning AMCP's engagement with diverse stakeholders to find comprehensive, patient-centric solutions and advocate for policy changes like the MVP Act to address rising costs and access challenges.
Read More